This morning, Chardan Healthcare Acquisition Corp. (CHACU) filed for a $70 million, Chardan-backed SPAC focusing on Healthcare companies in North America. Chardan Healthcare will be led by senior members of Chardan Capital Markets, a veteran SPAC underwriter.
Gbola Amusa, who has served as Partner, Director of Research, and Head of Healthcare Equity Research at Chardan Capital Markets since December 2014, will be Chairman of the Board for this team and Jonas Grossman, the current Partner and Head of Capital Markets for Chardan, will be leading as President and CEO. Finally, George Kaufman, who is currently Managing Director and Head of Investment Banking, will be CFO and Head of Strategy.
Looking at this SPAC’s structure, these terms look very aggressive. Of the five deals currently on file (CF Finance, Monocle, Schultze, Andina III, Chardan Healthcare), only Chardan Healthcare is offering a 1/2 share in their warrant. AND, it’s the only SPAC on file with a 24 month life. On top of that, the warrant trigger to call the warrants for redemption is set at >$16.00, rather than the standard >$18.00. (We’ll be putting together a comparison of all five, shortly)
Additionally, you will also notice that the underwriting fee is not being split as upfront/deferred. That’s because Chardan has decided to take a flat fee of just $500K, which makes sense since this is their deal and by lowering the underwriting fee, it reduces the amount of at-risk capital needed to bring the trust to 100%. However, they are purchasing their at-risk capital warrants at $0.40.
Since there is a conflict of interest with Chardan Capital Markets underwriting a SPAC with Chardan as a sponsor, Chardan Healthcare will be utilizing B. Riley FBR as their Qualified Independent Underwriter, but again, just like CF Finance, the QIU is not on the cover. That’s branding, folks. Both Chardan and Cantor want their deals to be 100% their own.
It remains to be seen if Chardan Healthcare will stick with these terms given the comparison to the other four SPACs currently on file. It’s aggressive for sure, but it’s a lot easier to start high rather than work your way up from low.
Chardan is sole book-running manager.
Loeb & Loeb LLP and Schiff Hardin LLP are issuer’s counsel and underwriter’s counsel, respectively.
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....